QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
Log in
NASDAQ:CLLS

Cellectis Stock Forecast, Price & News

$25.37
+1.16 (+4.79 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$23.78
Now: $25.37▼
$25.37
50-Day Range
$15.87
MA: $19.22▼
$24.21
52-Week Range
$7.32
Now: $25.37▼
$25.37
Volume145,517 shs
Average Volume170,816 shs
Market Capitalization$1.08 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.26
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.
Cellectis logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.40 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLLS
Previous Symbol
CUSIPN/A
CIK1627281
Webwww.cellectis.com
Phone33-1-81-69-16-00
Employees253

Debt

Debt-to-Equity Ratio0.10
Current Ratio6.11
Quick Ratio6.00

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.99 million
Price / Sales46.88
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.68 per share
Price / Book3.30

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-102,090,000.00
Net Margins-110.52%
Return on Equity-23.56%
Return on Assets-16.69%

Miscellaneous

Outstanding Shares42,486,000
Market Cap$1.08 billion
Next Earnings Date3/3/2021 (Estimated)
OptionableOptionable
$25.37
+1.16 (+4.79 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cellectis (NASDAQ:CLLS) Frequently Asked Questions

How has Cellectis' stock been impacted by COVID-19 (Coronavirus)?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLLS stock has increased by 122.0% and is now trading at $25.37.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Cellectis?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cellectis or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cellectis?

Wall Street analysts have given Cellectis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cellectis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Cellectis.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) issued its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.02. Cellectis had a negative net margin of 110.52% and a negative return on equity of 23.56%.
View Cellectis' earnings history.

What price target have analysts set for CLLS?

7 Wall Street analysts have issued 1-year price targets for Cellectis' stock. Their forecasts range from $11.00 to $73.00. On average, they expect Cellectis' stock price to reach $34.83 in the next twelve months. This suggests a possible upside of 37.3% from the stock's current price.
View analysts' price targets for Cellectis.

Are investors shorting Cellectis?

Cellectis saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 844,700 shares, an increase of 16.8% from the October 15th total of 723,400 shares. Based on an average daily trading volume, of 171,700 shares, the short-interest ratio is currently 4.9 days. Currently, 2.0% of the company's stock are short sold.
View Cellectis' Short Interest.

Who are some of Cellectis' key competitors?

Some companies that are related to Cellectis include Vir Biotechnology (VIR), Ablynx (ABLYF), SpringWorks Therapeutics (SWTX), bluebird bio (BLUE), Beam Therapeutics (BEAM), Revolution Medicines (RVMD), AlloVir (ALVR), Replimune Group (REPL), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), Kymera Therapeutics (KYMR), Editas Medicine (EDIT), Atara Biotherapeutics (ATRA), Forma Therapeutics (FMTX) and Mesoblast (MESO).
View all competitors.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • Dr. André Choulika, Co-Founder, Chairman & CEO (Age 55, Pay $1M)
  • Dr. David J. D. Sourdive, Co-Founder, Exec. VP of Strategic Initiatives & Director (Age 53, Pay $452.66k)
  • Mr. Eric Dutang, Chief Financial Officer (Age 46)
  • Mr. Jean Charles Epinat, Chief Technological Officer
  • Mr. Stephan Reynier, Chief Regulatory & Compliance Officer (Age 51)
  • Ms. Marie-Bleuenn Terrier, Gen. Counsel (Age 38)
  • Ms. Jennifer Moore, VP of Communications
  • Dr. Philippe Duchateau Ph.D., Chief Scientific Officer (Age 57)
  • Dr. Stéphane Dépil, Sr. VP of R&D and Chief Medical Officer (Age 46)
  • Mr. Jon Voss, Exec. VP of Global Quality (Age 60)

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.73%), Nikko Asset Management Americas Inc. (1.58%), Morgan Stanley (1.23%), Bpifrance SA (1.00%), BlackRock Inc. (0.41%) and Eqis Capital Management Inc. (0.24%).

Which major investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Nikko Asset Management Americas Inc., BlackRock Inc., New York State Common Retirement Fund, Victory Capital Management Inc., Acadian Asset Management LLC, Wells Fargo & Company MN, and Capital Asset Advisory Services LLC.

Which major investors are buying Cellectis stock?

CLLS stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Bpifrance SA, Eqis Capital Management Inc., Exchange Traded Concepts LLC, Jane Street Group LLC, KBC Group NV, OLD Mission Capital LLC, and OneAscent Financial Services LLC.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $25.37.

How big of a company is Cellectis?

Cellectis has a market capitalization of $1.08 billion and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 253 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.